Ariana Mullin
![Ariana Mullin Ariana Mullin](https://neuropsychiatric-drug-development.com/wp-content/uploads/sites/83/2024/05/Ariana-Mullin-150x150.jpg)
Company: Bristol Myers Squibb
Job title: Director
Seminars:
Panel Discussion | Moving the Gold Standard Beyond Subjective Mood Scales & Evaluating the Potential of Surrogate Endpoints 10:15 am
What are the right endpoints to use in indications, such as substance use disorder, where a defined mood scale is not clear? Critically evaluating the value of Hamilton and MADRS scales: are there different, more objective ways of tracking the severity of various psychological illnesses? Are we close to having a surrogate in psychiatry with…Read more
day: Conference Day 2 AM